Loading
REGN7508 / Cancer Associated Thrombosis (CAT) · Phase 3 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized placebo-controlled trial of REGN7508 for cancer-associated thrombosis prevention in adults with solid tumors undergoing or planning anticancer treatment. The trial is currently recruiting and has not reported results; the planned primary endpoints are time-to-first VTE/ATE or related death and time-to-first major/CRNM bleeding, both assessed through 6 months.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Cancer-Associated Thrombosis (CAT); age from 18 Years. Intervention: REGN7508. Compared with: Placebo — Placebo Comparator. n = 1,120. 14 sites: United States, Georgia, Japan.
This is a Phase 3 randomized placebo-controlled trial of REGN7508 for cancer-associated thrombosis prevention in adults with solid tumors undergoing or planning anticancer treatment. The trial is currently recruiting and has not reported results; the planned primary endpoints are time-to-first VTE/ATE or related death and time-to-first major/CRNM bleeding, both assessed through 6 months.
This is a registry record with no posted results; no efficacy or safety data are available. Follow-up duration is stated as 6 months for primary endpoints, but total study duration and long-term safety follow-up are not specified.
The source did not state who this applies to in practice.
This is a Phase 3 trial registration with no results posted; the study is actively recruiting and outcomes have not yet been reported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07410117). This is a study registration, not published results. Lead sponsor: Regeneron Pharmaceuticals. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1120 participants (ESTIMATED). Conditions: Cancer-Associated Thrombosis (CAT). Interventions: DRUG: REGN7508; DRUG: Placebo. Primary outcome measures: Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death , Through 6 months; Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleeding , Through 6 months. Brief summary: This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.